US/UK/Canada

Share

Quotes

We are excited that Nordic Blue with their experience and success in the field of wound care continue to believe and are willing to support Regenics in the further development of Collex®. Their investment and participation at the board level have been of great value this past year and we look forward to continuing our successful collaboration
Jan Alfheim
We continue to see tremendous potential in Regenics and its wound care products. Collex® represents an effective and sustainable approach to wound care, and we are proud to continue supporting its development. With Regenics’ strong scientific foundation and clear clinical focus, we believe the company is well-positioned to make a meaningful impact in the wound care market. Our increased investment reflects our confidence in the team and in the broader vision of building value through marine-based biotech innovation
Brynjolfur Eyjolfsson, Fund Manager, Haf Investments and chairman of Nordic Blue hf. commented
We believe Jostein is an excellent choice for the CEO role and that he will be a strong addition to the Regenics team
Jan Alfheim
His experience and knowledge in wound healing product development will be essential to the successful development of Collex®
Jan Alfheim
Pick a time period -
Tags ( Active)

Regenics Convenes Inaugural Scientific Advisory Board

Regenics is proud to announce the successful convening of its first Scientific Advisory Board (SAB) meeting, marking a significant milestone in the company’s mission to advance next-generation wound healing technologies. The SAB brings together leading experts in wound care, clinical medicine and research, including Dr. Christoph Wallner, Dr. Davíð Jensson, and Professor Dr. Guttorm Haraldsen, alongside Regenics’ leadership team: CEO Jostein Grip, Chief Scientific Officer Karin Gilljam and Chief Medical Officer Karl Bryn. The inaugural meeting focused on Regenics’ advanced wound

Regenics Appoints Brynjólfur Gísli Eyjólfsson as Chair of the Board

Regenics AS, a Norwegian biotech company developing advanced marine-based wound care products, announces the appointment of Brynjólfur Gísli Eyjólfsson as Chair of the Board of Directors. The appointment was approved at the company’s General Meeting held on Monday, June 16. Mr. Eyjólfsson brings extensive experience from the blue economy and investment sectors. He currently serves as Fund Manager for the IS Haf Fund, the largest investor in Nordic Blue ehf., which in turn owns 38.1% of Regenics through its participation in two financing rounds.Tohether with the remaining board members

Regenics AS completes second tranche of private placement to continue development of Collex®

Regenics announces the second closing of its non-brokered private placement offering, first announced on the 13[th] of August 2024, of up to 2,523,647 working capital units (the "WC Units") of the Company at a price of NOK 8,1 per unit. Each Unit consisted of one common share in Regenics AS and one- and one-half share purchase warrants (a "Warrant"). Each Warrant entitled Nordic Blue to purchase one common share, at a price of NOK 9 per unit, representing an additional capital raise of 33,2 MNOK, both of which constitute the "Offering.", from Nordic Blue esf., an Icelandic venture capital

Regenics AS appoints Jostein Grip as new CEO

New CEO brings a wealth of experience in the development of novel wound healing products.Press Release 01.2025   Regenics AS appoints Jostein Grip as new CEO   Oslo, 19. May 2025   Regenics AS, a private Norwegian biotechnology company based in Oslo, today announced that it has appointed Jostein Grip as the company’s new CEO. Jostein Grip has a PhD from the University in Tromsø.  His PhD thesis is entitled “Development of novel wound dressings with soluble beta-glycan (SBG®) as an active ingredient”.  Grip comes to Regenics from Oxy Solutions where he was CTO, and he

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe